Every product sold through First Alarm Health is strictly for research use only. Not for human consumption, not a medical treatment, not FDA-approved for the uses discussed on this site.
That's not a wink-wink loophole. It's the accurate legal and regulatory status for most of these compounds in the U.S. right now.
Here's why the gap exists, and it has nothing to do with safety. Getting a compound through the full FDA approval pipeline costs $1 to $2 billion and takes 10 to 15 years. That bet only makes sense for a company if it can patent the compound and sell it exclusively long enough to earn the money back. A lot of the peptides discussed on this site, BPC-157 is the textbook case, are naturally occurring sequences that are difficult or impossible to patent. Nobody's funding that math. So the approval gap is a patent-economics problem, not a verdict on safety.
That said, some peptides in this category are FDA-approved prescription drugs (semaglutide, tesamorelin, among others). Others, like BPC-157, are not approved, and the FDA has taken active steps limiting how compounding pharmacies can use it. That's a real distinction worth knowing, not just fine print. Check the article for a specific peptide if you want that peptide's actual regulatory status, it's not the same answer across the board. Start with Peptides 101 for the fuller version of this breakdown.
None of this is medical advice. Talk to your doctor before starting anything, especially if you have an existing health condition.